Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya.
about
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria.Plasmodium falciparum isolates with increased pfmdr1 copy number circulate in West Africa.High prevalence of pfmdr1 N86Y and Y184F mutations in Plasmodium falciparum isolates from Bioko Island, Equatorial GuineaFixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine.Molecular markers of anti-malarial drug resistance in southwest Ethiopia over time: regional surveillance from 2006 to 2013.Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya.Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the futureRepeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impactPrevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan.Fitness Consequences of Plasmodium falciparum pfmdr1 Polymorphisms Inferred from Ex Vivo Culture of Ugandan ParasitesIncreased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy.Plasmodium falciparum Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination Therapypfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.Analysis of major genome loci underlying artemisinin resistance and pfmdr1 copy number in pre- and post-ACTs in western Kenya.Inhibitory activity of ferroquine, versus chloroquine, against western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay.pfmdr1 amplification associated with clinical resistance to mefloquine in West Africa: implications for efficacy of artemisinin combination therapies.Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis.In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria.Plasmodium falciparum with multidrug resistance 1 gene duplications, Senegal.Amodiaquine resistance in Plasmodium berghei is associated with PbCRT His95Pro mutation, loss of chloroquine, artemisinin and primaquine sensitivity, and high transcript levels of key transporters.
P2860
Q33676088-4D7827AB-925C-411C-9C12-2B7B17AC717FQ33721915-2FC65A66-D772-4C99-B24C-1CBA2F2B7A18Q33962907-29F36B8F-4978-419D-B199-D4FD4FE2BE0AQ34562754-B79C0D23-6D5A-4924-A3C6-79C41EBC50A0Q34996451-529EE27D-174F-49CA-BD9B-3977E80E1B32Q35364589-B933AE42-207B-4B0D-B4B8-C34D08355979Q35814367-7766D856-0578-4E87-B75C-6E59EC7035EBQ35849636-743787D4-FB70-43A9-AB5A-B10131B60407Q36012531-EEFE2560-1916-4754-881B-51B57EA22949Q36080127-FFE45933-8D28-4C91-9AF2-4A674263B01CQ36316217-F057B5CF-C135-4664-A7BF-F1EE4BB468FFQ37038288-A09C4EBE-F139-433D-9855-B617CA05DFD8Q37124235-DEE3FD15-6D2C-4698-9CB3-6175F3BBAE40Q37285721-49AF770E-FB3F-4306-8AEF-E0B09705AD28Q37538729-05A30CB8-EFDD-4BEF-A5D3-814EA5072BC6Q39206934-76E0B8CA-F1F7-4337-B61D-058F77EA0EBCQ39301470-281C9315-BDD8-4CBF-A89F-CFAC1CFD6B30Q39410793-38874769-61F4-4DA5-9624-DC260C21AA76Q41777813-AA5A2645-DA19-420E-84BB-EC97C8981938Q41932353-876705EF-6B95-4CA2-B6EA-DB037CDE0D03Q41937598-6EDC4A7D-3D66-4EAD-9F62-41A15E50E6AFQ41940547-D72CA3BD-92B5-4B1D-BC2B-E18580B7ED68Q43171585-E2807A7A-2952-4E7C-B24E-AC30387C8075Q55286880-45EE46D9-AC6B-40E1-B1CE-957B8BF14933
P2860
Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Amodiaquine resistance is not ...... gene amplifications in Kenya.
@en
Amodiaquine resistance is not ...... gene amplifications in Kenya.
@nl
type
label
Amodiaquine resistance is not ...... gene amplifications in Kenya.
@en
Amodiaquine resistance is not ...... gene amplifications in Kenya.
@nl
prefLabel
Amodiaquine resistance is not ...... gene amplifications in Kenya.
@en
Amodiaquine resistance is not ...... gene amplifications in Kenya.
@nl
P2860
P921
P1476
Amodiaquine resistance is not ...... gene amplifications in Kenya.
@en
P2093
Gabrielle Holmgren
P2860
P304
P356
10.1111/J.1365-3156.2006.01742.X
P577
2006-12-01T00:00:00Z